Cellectis Details In Vivo Editing Reorganization

Company Cellectis Event Type Reorganization update and preclinical data Modality In vivo base editing and epigenetic silencing (LNP-mRNA) Asset .HEAL-101 (APOC3); .HEAL-201 (PCSK9) Target APOC3; PCSK9 Disease Area Severe hypertriglyceridemia; severe hypercholesterolemia Summary Cellectis reported further operating consequences of its previously announced shift to in…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *